Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

Impact · against what's priced in

The CHMP's positive opinion for the WELIREG and lenvatinib combination provides a modest near-term catalyst for Merck by supporting its required revenue growth, though it is secondary to the mRNA vaccine. For Eisai, this represents a tangible expansion of the addressable market for its discovered kinase inhibitor.

MRK+0.15

Challenges what's priced in